Back

Sex-specific drug-target Mendelian randomisation on the effects of lipid-modifying targets on cardiovascular disease

3 April 2025 (08:00 - 19:00)
Organised by: Logo
Congress Presentation Part of: Genetic mechanisms of cardiovascular risk Lipid-Lowering Agents EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Associate Professor Lena Tschiderer

Medical University of Innsbruck, Innsbruck (Austria)

4 More presentations in this session

Presentation thumbnail
Cardiorespiratory fitness, cardiovascular health, and other chronic diseases: a phenome-wide Mendelian randomization study
Mrs E. Fornara (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Genetic interleukin-6 receptor blockade, chronic disease risk and longevity
Doctor S. Wissel (Wurzburg, DE)
Abstract Slides
Presentation thumbnail
Polygenic prediction of cardiorespiratory fitness and relation to cardiovascular disease: the HUNT study
Miss M. Klevjer (Trondheim, NO)
Abstract Slides
Presentation thumbnail
Homozygous familial hypercholesterolemia Evaluation and Survival study in Saudi Arabia (HESSA): genetic and molecular characteristics of the largest genetic cohort in the middle east
Assistant Professor N. Kholaif (Riyadh, SA)
Abstract Slides

Access the full session

Session thumbnail
Genetic mechanisms of cardiovascular risk

The Event

Event poster

ESC Preventive Cardiology 2025

3 April - 5 April 2025
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
What’s new in LDL lowering?
thumbnail
Congress Presentation
Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources